- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - - Company expects proceeds to extend cash runway into 2026 - WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc.

-赛诺菲将以每股7.44美元的转换价格投资4000万美元——赛诺菲将获得公司小分子TREM2激动剂计划（包括目前正在进行第一阶段临床研究的VG-3927）许可证首次谈判的专有权——公司预计收益将延长至2026年——马萨诸塞州沃特敦（WATERTOWN），2024年6月27日（Global NEWSWIRE）——Vigil Neuroscience，Inc。

(Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock.

（纳斯达克股票代码：VIGL）是一家致力于利用小胶质细胞治疗神经退行性疾病的临床阶段生物技术公司，它很高兴地宣布，赛诺菲（纳斯达克股票代码：SNY）已以每股7.44美元的转换价格对该公司进行了4000万美元的战略投资。

Sanofi will purchase 537,634 of the Company’s Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities. “We are excited by this strategic investment from Sanofi, one of the world’s leading biopharmaceutical companies, for our research and development programs,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.

赛诺菲将购买公司A系列无投票权优先股537634股，每股可转换为10股普通股。该公司将使用收益资助其研发活动。

“We view Sanofi’s investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG-3927, and Sanofi has provided valuable capital to help fund our pipeline. We look forward to the opportunity to work with Sanofi as we continue to advance our small molecule TREM2 agonist program.” “Recent discoveries have highlighted the role of microglial signaling and neuroinflammation in neurodegenerative diseases.

“我们认为赛诺菲对Vigil的投资是对我们两种不同的TREM2模式（iluzanebart和VG-3927）领导的有前途的精准医学方法的验证，赛诺菲为我们的管道提供了宝贵的资金。我们期待有机会与赛诺菲合作，继续推进我们的小分子TREM2激动剂计划。”“最近的发现突出了小胶质细胞信号传导和神经炎症在神经退行性疾病中的作用。

TREM2 is a well credentialed microglia target in this context,” said Erik Wallstroem, .

在这种情况下，TREM2是一个公认的小胶质细胞靶标，”埃里克·沃尔斯特伦说。